3N Bio
3N Bio is a life science start-up spun off from SciLifeLab/Karolinska Institutet, focusing on microbial metadegradomics to enhance the development of small molecules that modulate the microbiome. Their technology provides immediate information on the effect of new drug substances on the microbiome, aiming to speed up diagnosis of phenotypic antimicrobial resistance and improve patient outcomes. Their mission is to develop quick, simple tests for detecting antimicrobial resistance to enable fast diagnosis, personalized treatment, and rational antibiotic use.
Industries
Nr. of Employees
small (1-50)
Products
Rapid culture-independent antimicrobial resistance diagnostic (in development)
A molecular diagnostic approach under development that uses bacterial mRNA degradation signatures to determine phenotypic response to antibiotics quickly from complex samples without culture or isolation.
Rapid culture-independent antimicrobial resistance diagnostic (in development)
A molecular diagnostic approach under development that uses bacterial mRNA degradation signatures to determine phenotypic response to antibiotics quickly from complex samples without culture or isolation.
Services
Collaborative R&D for rapid AMR diagnostics
Partnerships and collaborative research to develop rapid, molecular diagnostics that infer bacterial growth and drug response from RNA decay signatures.
Collaborative R&D for rapid AMR diagnostics
Partnerships and collaborative research to develop rapid, molecular diagnostics that infer bacterial growth and drug response from RNA decay signatures.
Expertise Areas
- Phenotypic antimicrobial susceptibility testing
- Culture-independent molecular diagnostics
- mRNA translation and decay research
- Microbiome–drug interaction studies
Key Technologies
- mRNA translation and decay analysis
- RNA sequencing
- Sequence-based profiling of RNA degradation patterns
- Culture-independent molecular assays